Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 April 2000Website:
http://www.sangamo.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 23:54:13 GMTDividend
Analysts recommendations
Institutional Ownership
SGMO Latest News
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast.
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg Research at ESGCT.
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.29 per share a year ago.
Final results from the phase 3 AFFINE trial using giroctocogene fitelparvovec for the treatment of patients with Hemophilia A are expected in the 1st half of 2024. If phase 3 trial is successful, Pfizer will be able to file BLA to the FDA of giroctocogene fitelparvovec for the treatment of patients with Hemophilia A 2nd half 2024.
What type of business is Sangamo Therapeutics?
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
What sector is Sangamo Therapeutics in?
Sangamo Therapeutics is in the Healthcare sector
What industry is Sangamo Therapeutics in?
Sangamo Therapeutics is in the Biotechnology industry
What country is Sangamo Therapeutics from?
Sangamo Therapeutics is headquartered in United States
When did Sangamo Therapeutics go public?
Sangamo Therapeutics initial public offering (IPO) was on 06 April 2000
What is Sangamo Therapeutics website?
https://www.sangamo.com
Is Sangamo Therapeutics in the S&P 500?
No, Sangamo Therapeutics is not included in the S&P 500 index
Is Sangamo Therapeutics in the NASDAQ 100?
No, Sangamo Therapeutics is not included in the NASDAQ 100 index
Is Sangamo Therapeutics in the Dow Jones?
No, Sangamo Therapeutics is not included in the Dow Jones index
When does Sangamo Therapeutics report earnings?
The next expected earnings date for Sangamo Therapeutics is 09 August 2024